Octreotide in Combination with TACE in Prevention of Relapse and Metastasis after Radical Operation for Primary Hepatocellular Carcinoma

王涌,彭承宏,刘颖斌,刘宏,赵之明,韩宝三

DOI: https://doi.org/10.3760/cma.j.issn.1007-8118.2004.09.007

2004-01-01

Abstract:Objective To explore the safe dosage of octreotide given through hepatic artery and investigate the prophylactic effects of remedy by combined use of octreotide and TACE on relapse and metastasis after radical operation for primary hepatocellular carcinoma (HCC). Methods Forty patients receiving radical excision were randomized into the study group and control group and were all given drugs through hepatic artery pump. For the study group, the first day's dosage was octreotide 200 μg, mixture of CDDP and lipiodol 18 ml (CDDP 40 mg/8ml + superliquefied lipiodol 10 ml). The second day's dosage was octreotide 200 μg. For the control group, only mixture of CDDP and lipiodol 18 ml was given on the first day. The remedy was repeated every 4-8 weeks. Then we observed their side effects and conducted a short-term follow-up study. Results The side effects were similar between the two groups. There were no obvious damages in important organs such as heart, liver and kidney. Face hectic fever with or without total body hectic fever was the only and transient reaction to administration of octreotide through the artery. Follow-up study showed that 1-year relapse rate, extrahepatic metastasis rate and mortality were 25%, 5% and 10% in the study group but 45%, 20% and 25% in the control. There were significant differences between the two groups. Conclusions Administration of 200 μg octreotide through the hepatic artery is safe. The remedy by combined use of octreotide and TACE is effective for prevention of relapse and metastasis after radical operation in a short period of time.